RNA-seq identification of RACGAP1 as a metastatic driver in uterine carcinosarcoma

Shijun Mi, Mingyan Lin, Jurriaan Brouwer-Visser, Jennifer Heim, David Smotkin, Tiffany M. Hebert, Marc J. Gunter, Gary L. Goldberg, Deyou Zheng, Gloria S. Huang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: Uterine carcinosarcoma is a rare aggressive malignancy frequently presenting at advanced stage of disease with extrauterine metastases. Median survival is less than 2 years due to high relapse rates after surgery and poor response to chemotherapy or radiotherapy. The goal of this study was to identify novel therapeutic targets. Experimental Design: We applied RNA-seq analysis to prospectively collected uterine carcinosarcoma tumor samples from patients undergoing primary surgical resection and for comparison, normal endometrial tissues from postmenopausal women undergoing hysterectomy for benign indications. Functional assays were done in primary carcinosarcoma cell lines developed from patients and in established cell lines, as well as a cell line-derived xenograft model. Validation was done by analysis of an independent cohort of patients with uterine carcinosarcoma from The Cancer Genome Atlas (TCGA). Results: Rac GTPase-activating protein 1 (RACGAP1) was identified to be highly upregulated in uterine carcinosarcoma. Functional assays showed that RACGAP1 mediates motility and invasion via regulation of STAT3 phosphorylation and survivin expression. RACGAP1 depletion or survivin inhibition abrogated motility and invasiveness of carcinosarcoma cells, while RACGAP1 overexpression conferred invasiveness to endometrial adenocarcinoma cells. In the TCGA cohort, RACGAP1 expression correlated with survivin expression and extrauterine spread of disease. Conclusions: The RACGAP1-STAT3-survivin signaling pathway is required for the invasive phenotype of uterine carcinosarcoma and is a newly identified therapeutic target in this lethal disease. Clin Cancer Res; 22(18); 4676-86.

Original languageEnglish (US)
Pages (from-to)4676-4686
Number of pages11
JournalClinical Cancer Research
Volume22
Issue number18
DOIs
StatePublished - Sep 15 2016

Fingerprint

rac GTP-Binding Proteins
Carcinosarcoma
GTPase-Activating Proteins
RNA
Atlases
Neoplasms
Cell Line
Genome
Hysterectomy
Heterografts
Adenocarcinoma
Cohort Studies
Research Design
Radiotherapy
Phosphorylation
Neoplasm Metastasis
Phenotype
Recurrence
Drug Therapy
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

RNA-seq identification of RACGAP1 as a metastatic driver in uterine carcinosarcoma. / Mi, Shijun; Lin, Mingyan; Brouwer-Visser, Jurriaan; Heim, Jennifer; Smotkin, David; Hebert, Tiffany M.; Gunter, Marc J.; Goldberg, Gary L.; Zheng, Deyou; Huang, Gloria S.

In: Clinical Cancer Research, Vol. 22, No. 18, 15.09.2016, p. 4676-4686.

Research output: Contribution to journalArticle

Mi, S, Lin, M, Brouwer-Visser, J, Heim, J, Smotkin, D, Hebert, TM, Gunter, MJ, Goldberg, GL, Zheng, D & Huang, GS 2016, 'RNA-seq identification of RACGAP1 as a metastatic driver in uterine carcinosarcoma', Clinical Cancer Research, vol. 22, no. 18, pp. 4676-4686. https://doi.org/10.1158/1078-0432.CCR-15-2116
Mi, Shijun ; Lin, Mingyan ; Brouwer-Visser, Jurriaan ; Heim, Jennifer ; Smotkin, David ; Hebert, Tiffany M. ; Gunter, Marc J. ; Goldberg, Gary L. ; Zheng, Deyou ; Huang, Gloria S. / RNA-seq identification of RACGAP1 as a metastatic driver in uterine carcinosarcoma. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 18. pp. 4676-4686.
@article{ecc3de29293f4261b3f01ef89ec7da33,
title = "RNA-seq identification of RACGAP1 as a metastatic driver in uterine carcinosarcoma",
abstract = "Purpose: Uterine carcinosarcoma is a rare aggressive malignancy frequently presenting at advanced stage of disease with extrauterine metastases. Median survival is less than 2 years due to high relapse rates after surgery and poor response to chemotherapy or radiotherapy. The goal of this study was to identify novel therapeutic targets. Experimental Design: We applied RNA-seq analysis to prospectively collected uterine carcinosarcoma tumor samples from patients undergoing primary surgical resection and for comparison, normal endometrial tissues from postmenopausal women undergoing hysterectomy for benign indications. Functional assays were done in primary carcinosarcoma cell lines developed from patients and in established cell lines, as well as a cell line-derived xenograft model. Validation was done by analysis of an independent cohort of patients with uterine carcinosarcoma from The Cancer Genome Atlas (TCGA). Results: Rac GTPase-activating protein 1 (RACGAP1) was identified to be highly upregulated in uterine carcinosarcoma. Functional assays showed that RACGAP1 mediates motility and invasion via regulation of STAT3 phosphorylation and survivin expression. RACGAP1 depletion or survivin inhibition abrogated motility and invasiveness of carcinosarcoma cells, while RACGAP1 overexpression conferred invasiveness to endometrial adenocarcinoma cells. In the TCGA cohort, RACGAP1 expression correlated with survivin expression and extrauterine spread of disease. Conclusions: The RACGAP1-STAT3-survivin signaling pathway is required for the invasive phenotype of uterine carcinosarcoma and is a newly identified therapeutic target in this lethal disease. Clin Cancer Res; 22(18); 4676-86.",
author = "Shijun Mi and Mingyan Lin and Jurriaan Brouwer-Visser and Jennifer Heim and David Smotkin and Hebert, {Tiffany M.} and Gunter, {Marc J.} and Goldberg, {Gary L.} and Deyou Zheng and Huang, {Gloria S.}",
year = "2016",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-15-2116",
language = "English (US)",
volume = "22",
pages = "4676--4686",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - RNA-seq identification of RACGAP1 as a metastatic driver in uterine carcinosarcoma

AU - Mi, Shijun

AU - Lin, Mingyan

AU - Brouwer-Visser, Jurriaan

AU - Heim, Jennifer

AU - Smotkin, David

AU - Hebert, Tiffany M.

AU - Gunter, Marc J.

AU - Goldberg, Gary L.

AU - Zheng, Deyou

AU - Huang, Gloria S.

PY - 2016/9/15

Y1 - 2016/9/15

N2 - Purpose: Uterine carcinosarcoma is a rare aggressive malignancy frequently presenting at advanced stage of disease with extrauterine metastases. Median survival is less than 2 years due to high relapse rates after surgery and poor response to chemotherapy or radiotherapy. The goal of this study was to identify novel therapeutic targets. Experimental Design: We applied RNA-seq analysis to prospectively collected uterine carcinosarcoma tumor samples from patients undergoing primary surgical resection and for comparison, normal endometrial tissues from postmenopausal women undergoing hysterectomy for benign indications. Functional assays were done in primary carcinosarcoma cell lines developed from patients and in established cell lines, as well as a cell line-derived xenograft model. Validation was done by analysis of an independent cohort of patients with uterine carcinosarcoma from The Cancer Genome Atlas (TCGA). Results: Rac GTPase-activating protein 1 (RACGAP1) was identified to be highly upregulated in uterine carcinosarcoma. Functional assays showed that RACGAP1 mediates motility and invasion via regulation of STAT3 phosphorylation and survivin expression. RACGAP1 depletion or survivin inhibition abrogated motility and invasiveness of carcinosarcoma cells, while RACGAP1 overexpression conferred invasiveness to endometrial adenocarcinoma cells. In the TCGA cohort, RACGAP1 expression correlated with survivin expression and extrauterine spread of disease. Conclusions: The RACGAP1-STAT3-survivin signaling pathway is required for the invasive phenotype of uterine carcinosarcoma and is a newly identified therapeutic target in this lethal disease. Clin Cancer Res; 22(18); 4676-86.

AB - Purpose: Uterine carcinosarcoma is a rare aggressive malignancy frequently presenting at advanced stage of disease with extrauterine metastases. Median survival is less than 2 years due to high relapse rates after surgery and poor response to chemotherapy or radiotherapy. The goal of this study was to identify novel therapeutic targets. Experimental Design: We applied RNA-seq analysis to prospectively collected uterine carcinosarcoma tumor samples from patients undergoing primary surgical resection and for comparison, normal endometrial tissues from postmenopausal women undergoing hysterectomy for benign indications. Functional assays were done in primary carcinosarcoma cell lines developed from patients and in established cell lines, as well as a cell line-derived xenograft model. Validation was done by analysis of an independent cohort of patients with uterine carcinosarcoma from The Cancer Genome Atlas (TCGA). Results: Rac GTPase-activating protein 1 (RACGAP1) was identified to be highly upregulated in uterine carcinosarcoma. Functional assays showed that RACGAP1 mediates motility and invasion via regulation of STAT3 phosphorylation and survivin expression. RACGAP1 depletion or survivin inhibition abrogated motility and invasiveness of carcinosarcoma cells, while RACGAP1 overexpression conferred invasiveness to endometrial adenocarcinoma cells. In the TCGA cohort, RACGAP1 expression correlated with survivin expression and extrauterine spread of disease. Conclusions: The RACGAP1-STAT3-survivin signaling pathway is required for the invasive phenotype of uterine carcinosarcoma and is a newly identified therapeutic target in this lethal disease. Clin Cancer Res; 22(18); 4676-86.

UR - http://www.scopus.com/inward/record.url?scp=84990876584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990876584&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-2116

DO - 10.1158/1078-0432.CCR-15-2116

M3 - Article

VL - 22

SP - 4676

EP - 4686

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -